Abbott Laboratories (ABT)

ABT (NYSE:Health Services) EQUITY
$37.41
pos +0.00
+0.00%
Today's Range: 37.12 - 38.35 | ABT Avg Daily Volume: 6,950,600
Last Update: 02/05/16 - 4:00 PM EST
Volume: 0
YTD Performance: -16.70%
Open: $0.00
Previous Close: $38.01
52 Week Range: $36.00 - $51.74
Oustanding Shares: 1,491,719,891
Market Cap: 56,700,273,057
6-Month Chart
TheStreet Ratings Grade for ABT
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 10 9 9
Moderate Buy 2 2 3 3
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.82 1.71 1.74 1.74
Latest Dividend: 0.26
Latest Dividend Yield: 2.74%
Dividend Ex-Date: 01/13/16
Price Earnings Ratio: 88.40
Price Earnings Comparisons:
ABT Sector Avg. S&P 500
88.40 12.70 30.32
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-17.20% -18.05% 10.55%
GROWTH 12 Mo 3 Yr CAGR
Revenue -7.30 -0.48 -0.19
Net Income -11.30 -0.64 -0.28
EPS -8.00 -0.50 -0.21
Earnings for ABT:
EBITDA 4.15B
Revenue 20.25B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.39 $0.53 $2.15 $2.45
Number of Analysts 10 9 12 13
High Estimate $0.40 $0.59 $2.18 $2.66
Low Estimate $0.38 $0.49 $2.14 $2.37
Prior Year $0.47 $0.52 $2.15 $2.15
Growth Rate (Year over Year) -17.23% 2.78% 0.00% 13.95%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bearish
Jan 29, 2016 | 7:21 AM EST
ABT was downgraded to Market Perform, William Blair said. Company continues to face earnings headwinds. 
Two significant, but subtle forces may threaten the group in the next 12 months.
The merged company can become multiple companies.
Bullish
Dec 07, 2015 | 7:24 AM EST
ABT was upgraded from Hold to Buy, Jefferies said. $55 price target. Growth platforms are likely to remain strong in emerging markets.&...
There's too much good out there.
Bearish
Nov 13, 2015 | 7:04 AM EST
ABT was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $48 price target. 

The Book of Boockvar Real Money Pro($)

Peter Boockvar looks at China, the European Central Bank and the Bank of Japan this morning:
Bullish
Oct 07, 2015 | 7:09 AM EDT
ABT was upgraded to Overweigt, Barclays said. $52 price target. Valuation call, after the stock is down 18% over the past six weeks.&nb...
Before you sell them, ask yourself at what multiple you sell.

AbbVie Has More Downside to Go Real Money Pro($)

The stock has shown awful relative strength.

Columnist Conversations

Flat as a pancake. Thus far, Jim "El Capitan" Cramer doesnt yet get his wish. http://realmoneypro.thestreet.co...
We had expected a recovery in energy prices and better things from the stocks for some time. So far, we have b...
Industrials have seen their revenues and earnings outlook slow in the past year due to a slowing China and a b...
Get your cues from market legends like Jesse Livermore... http://realmoneypro.thestreet.com/dougs-daily-diary?...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.